Takeda Pharmaceutical Company Limited (LON: 0A87)

Market Cap	33.21B
Revenue (ttm)	23.68B
Net Income (ttm)	1.51B
Shares Out	n/a
EPS (ttm)	0.95
PE Ratio	21.99
Forward PE	n/a
Dividend	0.41 (3.18%)
Ex-Dividend Date	Sep 30, 2024

Volume	3,428
Average Volume	1,262
Open	12.96
Previous Close	13.09
Day's Range	12.95 - 13.02
52-Week Range	10.01 - 11.99
Beta	n/a
RSI	43.58
Earnings Date	Jan 30, 2025

About Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A...

• Industry: Pharmaceutical Preparations
• Founded: 1781
• Employees: 49,281
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A87

Financial Performance

In 2023, Takeda Pharmaceutical Company's revenue was 4.26 trillion, an increase of 5.87% compared to the previous year's 4.03 trillion. Earnings were 144.07 billion, a decrease of -54.56%.

Financial numbers in JPY